We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Induced Pluripotent-Stem Cells Have Untapped Potential for Disease Treatment

By LabMedica International staff writers
Posted on 06 Sep 2011
A recent publication reviewed progress made over the past several years in applying induced pluripotent-stem cell (iPSC) technology to the treatment of human diseases such as Parkinson's disease, Alzheimer's disease, and cardiovascular disease.

iPSCs were first produced in 2006 from mouse cells and in 2007 from human cells. More...
In principle, the use of iPSCs presents several attractive alternatives to the use of human embryonic stem cells. In particular, use of iPSCs avoids the ethical dilemma surrounding the use of human embryonic cells. Also, the use of an individual’s own cells should eliminate or reduce the risk of rejection by the immune system.

Investigators at the University of California, Davis (USA) examined the difficulties that have arisen to prevent the widespread clinical use of iPSCs.

The reported in the August 5, 2010, issue of the journal Cell Stem Cell that while the pluripotent nature of iPSCs allows them to transform into mature cell types such as neurons, they also possess a serious potential for generating tumors. In addition, at least one study reported immune rejection of transformed by iPSCs by a patient who had provided the cells initially.

Nonetheless, the investigators feel that iPSCs remain a major untapped resource for treatment of certain diseases. “iPSCs offer the potential to treat many diseases as an alternative or adjuvant therapy to drugs or surgery,” said senior author Dr. Paul S. Knoepfler, associate professor of cell biology and human anatomy at the University of California, Davis. “Problems that have been identified with their use likely can be overcome, allowing iPSCs to jump from the laboratory dish to patients who could benefit from them. Future studies of iPSCs should increasingly focus on issues most relevant to the eventual clinical use of the cells, offering the fastest pathway to treating patients with this potentially powerful therapeutic tool.”

Related Links:

University of California, Davis



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Immunoassay Analyzer
Procise DX
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.